


Optimelt® Hot Melt Extrusion

Enabling solubility enhancement and differentiated oral dosage forms.

At Ardena, we support the development of advanced oral drug formulations through hot melt extrusion (HME). Now powered by the Optimelt® platform, our offering enables improved solubility, stability, and bioavailability – helping you move confidently from early development to clinical and commercial supply.

Our HME process



Why Choose Ardena

We offer a fully integrated service, from formulation screening and API-sparing feasibility studies to scalable HME processing and finished dosage forms. With in-house analytical support and a track record in handling complex and thermally sensitive APIs, our teams are ready to accelerate your program with flexibility and scientific depth.


ARDENA

info@ardena.com

www.ardena.com



Optimelt[®] Hot Melt Extrusion: Expertise that Scales



Science-Driven Formulation

We start with thermal and physical characterization of the API using techniques like DSC, TGA, and hot stage microscopy. These insights guide the selection of polymers and processing conditions to ensure stable amorphous solid dispersions with optimal performance.



Flexible Dose Forms

From immediate to modified release, we offer formulation pathways tailored to your molecule and therapeutic goals – all supported by integrated downstream processing and packaging capabilities.



Seamless Scale-Up

We apply SMEC-based modeling to streamline tech transfer and scale-up across extruder sizes. Our R&D and GMP environments are equipped with comparable equipment to ensure consistency and de-risk late-stage production.



End-to-End Support

Analytical method development, stability studies, regulatory support, all under one roof. From preclinical PK studies to commercial launch, we provide continuity and control across the lifecycle.

Talk with our experts about your
formulation challenge



info@ardena.com

www.ardena.com